Benitec Biopharma Inc. (NASDAQ:BNTC – Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 62,000 shares, a decline of 6.8% from the August 15th total of 66,500 shares. Based on an average trading volume of 29,200 shares, the days-to-cover ratio is presently 2.1 days.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on BNTC shares. Leerink Partnrs raised shares of Benitec Biopharma to a “strong-buy” rating in a research report on Monday, July 22nd. Piper Sandler initiated coverage on Benitec Biopharma in a research report on Thursday, June 13th. They set an “overweight” rating and a $30.00 price target for the company. Guggenheim assumed coverage on Benitec Biopharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, Leerink Partners began coverage on Benitec Biopharma in a research note on Monday, July 22nd. They issued an “outperform” rating and a $13.00 price objective for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $19.00.
View Our Latest Analysis on BNTC
Benitec Biopharma Trading Up 3.2 %
Hedge Funds Weigh In On Benitec Biopharma
Institutional investors and hedge funds have recently bought and sold shares of the company. Nantahala Capital Management LLC purchased a new position in shares of Benitec Biopharma during the 2nd quarter valued at $5,881,000. Simplify Asset Management Inc. purchased a new stake in Benitec Biopharma during the second quarter valued at about $358,000. GAMMA Investing LLC boosted its position in Benitec Biopharma by 53.0% during the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 1,884 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Benitec Biopharma by 35.5% in the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after purchasing an additional 64,092 shares in the last quarter. 52.19% of the stock is owned by institutional investors.
Benitec Biopharma Company Profile
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Recommended Stories
- Five stocks we like better than Benitec Biopharma
- Pros And Cons Of Monthly Dividend Stocks
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What Makes a Stock a Good Dividend Stock?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.